POWER: Prevention Options for Women Evaluation Research

AVAC

Status

Ongoing

Phase

Demo Project

Objective

Assesses women’s preferences for using microbicides and PrEP through demonstration projects with strategic pilots of delivery strategies, first with oral PrEP. Project will characterize choice, uptake, early adherence and identify cost-effective delivery models, including assessment of repeat HIV testing, decision-making within partnerships, and the interface with reproductive health services.  

May 4, 2020
Resource types
Websites or databases
Countries
Tags
clinical trial, oral PrEP

Similar Resources

Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.

A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection.

End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy.

Despite being designed for autonomous use, research suggests partner approval is often necessary in women's microbicide use.

Professor Quarraisha Abdool Karim is one of the world’s leading AIDS researchers and has made pioneering contributions to understanding the HIV epidemic in young people, especially among young women.

Injectable, intrauterine, and implantable contraceptives have been prioritised for programmatic delivery because of high contraceptive efficacy and safety. Robust evidence on the relative risks, particularly HIV susceptibility, and benefits of these contraceptive methods is important to inform…

This study has two phases. It will be conducted in one site in CT only. Phase I is to enumerate interest in PrEP uptake among young South African women exposed to a culturally-appropriate social marketing campaign.

Multipurpose prevention technologies (MPTs) are preferably single dosage forms designed to simultaneously address multiple sexual and reproductive health needs, such as unintended pregnancy, HIV infection and other sexually transmitted infections (STIs).

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence.